• If you are wondering whether Pfizer's current share price lines up with its fundamentals, this breakdown will help you focus on what the numbers actually say about value.
• The stock last closed at US$27.22, with returns of 0.0% over 7 days, a 0.8% decline over 30 days, an 8.1% gain year to date, and 31.9% over 1 year, while the 3 year and 5 year returns are 18.1% and 9.6% declines respectively.
• Recent headlines around Pfizer have focused on the company as a large, established pharmaceuticals player, with investors paying attention to how its pipeline, patent cycle and product mix are evolving. These themes often shape how the market weighs long term prospects against shorter term share price moves.
• Pfizer currently has a value score of 3 out of 6, which reflects how it screens across several standard valuation checks. Next up is a look at what those approaches show and why a broader way of thinking about valuation can be even more useful by the end of this article.

Approach 1: Pfizer Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth today by projecting its future cash flows and then discounting those back to a present value.

For Pfizer, the model used is a 2 Stage Free Cash Flow to Equity approach, relying on cash flow projections and a longer term fade period. The latest twelve month Free Cash Flow is about US$8.5b. Analyst and extrapolated estimates suggest Free Cash Flow of around US$16.1b by 2030, with interim projections between 2026 and 2035 ranging roughly from US$15.9b to US$19.9b before discounting.

When these projected cash flows are discounted back and aggregated, the DCF model points to an estimated intrinsic value of about US$63.97 per share. Compared with the recent share price of US$27.22, this implies a discount of roughly 57.4%, indicating that the shares are pricing in a lot of caution relative to the cash flow outlook embedded in this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Pfizer is undervalued by 57.4%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Approach 2: Pfizer Price vs Earnings (P/E)

For a profitable company like Pfizer, the P/E ratio is a useful shorthand for how much investors are currently paying for each dollar of earnings. It ties directly to what you see on the income statement, which makes it easier to relate the share price to the business today.

What counts as a “normal” P/E depends on how the market sees growth potential and risk. Higher expected growth or lower perceived risk often go with a higher P/E, while slower growth or higher uncertainty tend to justify a lower one.

Pfizer currently trades on a P/E of 19.99x. That is close to both the Pharmaceuticals industry average of 17.03x and the peer group average of 19.57x, so the market is not treating Pfizer as an obvious outlier on simple comparisons.

Simply Wall St’s Fair Ratio for Pfizer is 20.90x. This is a proprietary estimate of what Pfizer’s P/E might be given its earnings profile, industry, profit margins, market cap and company specific risks. Because it folds these factors into one figure, it can be more informative than looking at peers or industry averages alone.

Comparing the Fair Ratio of 20.90x with the current P/E of 19.99x suggests the shares are modestly below that level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Pfizer Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you turn your view of Pfizer into a clear story that ties together your assumptions for future revenue, earnings and margins with a Fair Value you can compare to the current share price.

In practice, a Narrative is your version of the company, built on numbers, where you connect themes like Pfizer’s post COVID transition, oncology and obesity pipeline, patent cliff risk, cost cuts and dividend policy to a financial forecast and a Fair Value estimate rather than relying only on ratios like P/E.

On the Simply Wall St Community page, Narratives are designed to be easy to use, so you can see how your view lines up against others. They update automatically when new data, news or earnings are added, helping you keep your Fair Value vs Price view current without rebuilding your model each time.

For Pfizer, one investor Narrative might lean optimistic, using assumptions similar to a Fair Value of about US$35.33 per share. A cautious Narrative might look closer to US$25.00, and comparing each to today’s price can help you decide whether the stock appears closer to fully valued or discounted under your own story.

For Pfizer however we will make it really easy for you with previews of two leading Pfizer Narratives:

Each one ties together different assumptions about the obesity pipeline, patent cycle and earnings path, so you can quickly see which version of the story feels closer to your own view.

Fair value: US$29.08

Implied discount to this fair value: 6.4%

Revenue growth assumption: 2.9% decline

• Sees long term support from an expanded late stage pipeline in oncology, rare diseases, vaccines and obesity treatments, alongside business development activity that widens the product base.
• Assumes efficiency gains from digitalisation, AI powered R&D and automation help support margins even while headline revenue expectations are for a 2.9% annual decline.
• Aligns with analyst consensus targets around US$28.86, with earnings projected to US$12.8b and a future P/E of 15.7x, subject to the usual execution and policy risks across pricing, regulation and patent expiries.

Fair value: US$25.00

Implied premium to this fair value: 8.9%

Revenue growth assumption: 6.7% decline

• Focuses on pressure from drug price negotiations, regulatory reforms and a sizeable patent cliff across products such as Eliquis and Ibrance, with revenue expected to decline by 6.7% per year.
• Assumes earnings fall to US$6.6b by 2029, with only a modest margin lift, and a higher 26.2x P/E required to support the more cautious US$25.00 fair value.
• Flags the risk that new GLP 1, oncology and other pipeline assets may not fully replace post 2028 revenue, while still acknowledging that cost programs, acquisitions and late stage trials could challenge this more pessimistic view.

If you want to see these stories in full, including all the underlying earnings paths, margins and key risks, you can step through the complete Pfizer Narratives side by side using the community tools on Simply Wall St, and then cross check which assumptions line up best with your own view of the stock today.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Pfizer on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Pfizer? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.